---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-399377"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2026-09-23T20:05:14+00:00"
generated_at: "2026-09-23T20:07:11.818188+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO settles patent litigation with Sarepta for $39M payment

## Summary
- Sarepta will pay $39.0 million to REGENXBIO within 10 days of settlement effective date (Sept 23, 2026).
- Settlement resolves all patent infringement litigation over U.S. Patent Nos. 10,526,617 and 11,680,274 related to ELEVIDYS (SRP-9001).
- Parties terminate litigation with prejudice; REGENXBIO and UPenn release current claims and covenant not to sue on AAVrh74-based products.
- Covenant covers existing ELEVIDYS form and AAVrh74 capsid sequence, but does not extend to other gene therapy aspects.

## SEC filing metadata
- accession: 0001193125-26-399377
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2026-09-23T20:05:14+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/0001193125-26-399377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/rgnx-20260923.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-399377
- JSON: https://secwatch.observer/filing/0001193125-26-399377.json
- Plain text: https://secwatch.observer/filing/0001193125-26-399377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.